U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555665) titled 'REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification' on Feb. 11.
Brief Summary: Despite the high incidence, endometrial cancer represents a low mortality neoplasma due to the high prevalence of early-stage diagnosis (90%). Concerning the uterine-confined disease (FIGO 2009 and 2023 stage I-II), molecular-based classification has showed an unprecedent impact on the treatment algorithm leading to a full integration into the latest staging classification. The first evidence of the prognostic value of molecular subgroups came from the TCGA data in which patients were subdivided into: patients with POLE gene alter...